Press releases
These press releases are intended for journalists and analysts/investors.
-
Doctors encouraging middle-aged Aussie blokes to consider their prostate
MJA Insight article highlights consequences of nation’s most common prostate condition, Benign Prostatic Hyperplasia – BPH1
-
Australia responds to changing humanitarian need with pioneering new health education course
Deakin University in partnership with global healthcare company GSK and not-for-profit humanitarian organisation Save the Children
-
New treatment reimbursed for major breathing disorder
Trelegy Ellipta (fluticasone furoate, umeclidinium and vilanterol) - first, once-daily triple therapy for COPD reimbursed by the PBS
-
GSK statement on influenza vaccine supply for the 2018 season
Due to high take up of flu vaccination in the last two months, reflecting the importance Australians are placing on helping protect
-
Nominations open for prestigious GSK Award for Research Excellence
Nominations for GSK’s Award for Research Excellence are now open until 2 July 2018
-
GSK Australia reports 2017 results to ASIC
GlaxoSmithKline (GSK) Australia has reported its 2017 results to the Australian Securities and Investment Commission (ASIC)
-
Discontinuation of Typherix adult vaccine
GSK has announced that Typherix [Salmonella typhi Vi polysaccharide vaccine] adult vaccine will be discontinued from supply and no longer
-
GSK launches Discovery Fast Track: Australian Challenge in search of early drug discovery partnerships with local researchers
GSK has launched its Discovery Fast Track Australian Challenge, a program designed to accelerate the translation of early-stage research
-
New report aims to broaden understanding of how new medicines are funded in Australia
GlaxoSmithKline Australia (GSK) and ViiV Healthcare (ViiV) have launched a new report as part of an initiative to raise understanding
-
GSK response to ACCC Voltaren comparison investigation
We are disappointed the ACCC has decided to commence proceedings against us
-
Australians embrace digital health but privacy remains top concern
Results of a new study commissioned by GlaxoSmithKline Australia (GSK) reveal that Australians are in a bind when it comes to healthcare
-
Update on GSK hepatitis vaccine availability
The following GSK hepatitis containing vaccines are experiencing supply constraints
-
Anne Belcher, Head of GSK Australia Pharmaceuticals, appointed to Medicines Australia Board
Anne Belcher, General Manager of GSK Australia Pharmaceuticals, has welcomed her appointment to the Medicines Australia (MA) Board
-
Leukaemia pioneer “customising” cancer treatment receives major research award
Prof. Timothy Hughes wins GSK Award for Research Excellence 2017. Clinical trials vital to making new discoveries, says winner
-
TGA approves MENVEO® vaccine to help protect babies from two months old from meningococcal disease
First ACWY combination vaccine available for use in infants under 12 months old, most at risk from meningococcal disease
-
Research shows hay fever nothing to sneeze at
Interior design guru Darren Palmer shares his hay fever story
-
GSK Hepatitis B vaccine availability
We are currently experiencing a supply constraint of Twinrix Adult (combined hepatitis A and B vaccine) due to a precautionary disruption
-
What Aussie parents need to know about meningococcal disease
Whilst 93 percent of Australian parents believe that they know what meningococcal disease is, on average nearly a third of Australian parent
-
The three letters making Australian men disappear
There’s a disease affecting one in three Australian men over 50
-
GSK confirms that Bexsero (meningococcal B vaccine) will be available for purchase in Australia next week
GSK has increased supply by an additional 200,000 doses of Bexsero (meningococcal B vaccine) which can be ordered
